"Le Centre hospitalier sur le site de Beausseret à Montélimar, est aujourd'hui un vaste établissement. Il dispose de 5 pôles où se répartissent différentes structures spécialisées d'examens et de soins ouvertes à tous les publics, aux différents âges de la vie. Mais un hôpital doté des derniers équipements technologiques de pointe, ne serait rien sans le personnel qui l'anime. C'est aussi notre conviction : faire vivre notre établissement en créant du lien. Créer un lien fort avec les patients que nous souhaitons accueillir dans les meilleures conditions d'équipements et d'infrastructures. Créer en amont un cadre de travail accueillant à notre personnel et faire rayonner cette dynamique dans un environnement favorable à un épanouissement."

During the past decade, Centre Hospitalier de Montélimar conducted 20 clinical trials. In the 10-year time frame, 20 clinical trials started and 2 clinical trials were completed, i.e. on average, 10% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 1 clinical trials were completed. i.e. 11.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centre Hospitalier de Montélimar" #1 sponsor was "Federation Francophone de Cancerologie Digestive" with 7 trials, followed by "Intergroupe Francophone de Cancerologie Thoracique" with 6 trials sponsored, "Centre Hospitalier Universitaire de Saint Etienne" with 3 trials sponsored, "ARCAGY/ GINECO GROUP" with 2 trials sponsored and "Fédération Française de Pneumologie" with 2 trials sponsored. Other sponsors include 16 different institutions and companies that sponsored additional 22 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centre Hospitalier de Montélimar" #1 collaborator was "CHU Saint-Etienne - Laboratoire de Pharmacologie - Toxicologie - Gaz du sang" with 2 trials as a collaborator, "Federation of Medical Specialties" with 2 trials as a collaborator, "GERCOR - Multidisciplinary Oncology Cooperative Group" with 2 trials as a collaborator, "ARCAGY/ GINECO GROUP" with 1 trials as a collaborator and "Association de Neuro-Oncologues d'Expression Francaise" with 1 trials as a collaborator. Other collaborators include 10 different institutions and companies that were collaborators in the rest 20 trials.

According to Clinical.Site data, the most researched conditions in "Centre Hospitalier de Montélimar" are "Breast Cancer" (6 trials), "Colorectal Cancer" (2 trials), "Colorectal Neoplasms" (2 trials), "Sars-CoV2" (2 trials) and "Surgery" (2 trials). Many other conditions were trialed in "Centre Hospitalier de Montélimar" in a lesser frequency.

Most popular intervention types in "Centre Hospitalier de Montélimar" are "Drug" (19 trials), "Other" (13 trials), "Device" (3 trials), "Procedure" (3 trials) and "Radiation" (3 trials). Other intervention types were less common.

The name of intervention was led by "Anastrozole" (2 trials), "Bevacizumab" (2 trials), "Docetaxel" (2 trials), "Gemcitabine" (2 trials) and "Letrozole" (2 trials). Other intervention names were less common.

The vast majority of trials in "Centre Hospitalier de Montélimar" are 33 trials for "All" genders and 8 trials for "Female" genders.

Currently, there are NaN active trials in "Centre Hospitalier de Montélimar". undefined are not yet recruiting, 5 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 25 completed trials in Centre Hospitalier de Montélimar, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Centre Hospitalier de Montélimar, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 17 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 4 trials that are defined as “Not Applicable".

Centre Hospitalier de Montélimar has several departments that took part in Clinical trials: "Ch De Montelimar; Gastro Enterologie Oncologie" - 2 trials